Literature DB >> 27401215

Mechanism of Self-Regulation and In Vivo Performance of the Cleveland Clinic Continuous-Flow Total Artificial Heart.

David Horvath1, Nicole Byram1, Jamshid H Karimov1, Barry Kuban1, Gengo Sunagawa1, Leonard A R Golding1, Nader Moazami1,2, Kiyotaka Fukamachi1.   

Abstract

Cleveland Clinic's continuous-flow total artificial heart (CFTAH) provides systemic and pulmonary circulations using one assembly (one motor, two impellers). The right pump hydraulic output to the pulmonary circulation is self-regulated by the rotating assembly's passive axial movement in response to atrial differential pressure to balance itself to the left pump output. This combination of features integrates a biocompatible, pressure-balancing regulator with a double-ended pump. The CFTAH requires no flow or pressure sensors. The only control parameter is pump speed, modulated at programmable rates (60-120 beats/min) and amplitudes (0 to ±25%) to provide flow pulses. In bench studies, passive self-regulation (range: -5 mm Hg ≤ [left atrial pressure - right atrial pressure] ≤ 10 mm Hg) was demonstrated over a systemic/vascular resistance ratio range of 2.0-20 and a flow range of 3-9 L/min. Performance of the most recent pump configuration was demonstrated in chronic studies, including three consecutive long-term experiments (30, 90, and 90 days). These experiments were performed at a constant postoperative mean speed with a ±15% speed modulation, demonstrating a totally self-regulating mode of operation, from 3 days after implant to explant, despite a weight gain of up to 40%. The mechanism of self-regulation functioned properly, continuously throughout the chronic in vivo experiments, demonstrating the performance goals.
© 2016 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Keywords:  Blood pump; Hemodynamics; Mock loop; Pressure regulation

Mesh:

Year:  2016        PMID: 27401215     DOI: 10.1111/aor.12780

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  5 in total

1.  Advantages of Integrating Pressure-Regulating Devices Into Mechanical Circulatory Support Pumps.

Authors:  David J Horvath; Jamshid H Karimov; Nicole A Byram; Barry D Kuban; Gengo Sunagawa; Nader Moazami; Kiyotaka Fukamachi
Journal:  ASAIO J       Date:  2019-01       Impact factor: 2.872

Review 2.  The ongoing quest for the first total artificial heart as destination therapy.

Authors:  Annemijn Vis; Maziar Arfaee; Husain Khambati; Mark S Slaughter; Jan F Gummert; Johannes T B Overvelde; Jolanda Kluin
Journal:  Nat Rev Cardiol       Date:  2022-06-06       Impact factor: 32.419

3.  Simulated Performance of the Cleveland Clinic Continuous-Flow Total Artificial Heart Using the Virtual Mock Loop.

Authors:  Takuma Miyamoto; David J Horvath; Dennis W Horvath; Jamshid H Karimov; Nicole Byram; Barry D Kuban; Kiyotaka Fukamachi
Journal:  ASAIO J       Date:  2019-08       Impact factor: 2.872

Review 4.  Advancements in mechanical circulatory support for patients in acute and chronic heart failure.

Authors:  Thomas A Csepe; Ahmet Kilic
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Computational Fluid Dynamics Model of Continuous-Flow Total Artificial Heart: Right Pump Impeller Design Changes to Improve Biocompatibility.

Authors:  Mark S Goodin; David J Horvath; Barry D Kuban; Anthony R Polakowski; Kiyotaka Fukamachi; Christine R Flick; Jamshid H Karimov
Journal:  ASAIO J       Date:  2022-09-20       Impact factor: 3.826

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.